Intellectual Property India Publishes Patent Application for Combination Therapy Involving Bispecific Binding Agents Binding To Cldn18.2 And Cd3 And Agents Stabilizing Or Increasing Expression Of Cldn18.2

MUMBAI, India, June 24 -- Intellectual Property India has published a patent application (202647069392 A) filed by Astellas Pharma Inc. on June 03, 2026, for Combination Therapy Involving Bispecific Binding Agents Binding To Cldn18.2 And Cd3 And Agents Stabilizing Or Increasing Expression Of Cldn18.2.

Inventors include Tanaka, Hiroaki; and Nakazawa, Taisuke.

The application for the patent was published on June 12, 2026, under issue no. 24/2026.

Abstract: The present invention provides a combination therapy involving bispecific binding agents comprising two binding domains binding to CLDN18.2 and a binding domain binding to CD3 and agents stabilizing or increasing the expression of CLDN 18.2. The combination therapy is effective in treating cancer involving cancer cells expressing CLDN18.2.

Disclaimer: Curated by HT Syndication.